MedTrace Logo

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT05743946 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-02-09

No results posted yet for this study

Summary

Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four weeks. The researchers will monitor clinical endpoints, quality of life, and weight. Additionally, cutaneous punch biopsy material material or blood samples from participants who agree to do this optional test will be collected to test cellular response to Trikafta.

Conditions

  • Non-cystic Fibrosis Bronchiectasis

Interventions

DRUG

Trikafta

Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be for 28 days, and otherwise identical to what has already been FDA-approved for effective treatment of cystic fibrosis.

Sponsors & Collaborators

  • The Marcus Foundation

    collaborator OTHER

  • Emory University

    lead OTHER

Principal Investigators

  • Eric Sorscher, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-18
Primary Completion
2025-12-23
Completion
2025-12-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05743946 on ClinicalTrials.gov